hackint0sh/New-Dataset huggingface dataset:
Researchers will compare the groups that receive or not ursodeoxycolic acid treatment to see if the polyp size evolution differs significantly. conditions: Gallbladder Polyp studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 36 type: ESTIMATED name: Ursodeoxycholic Acid Only Product measure: Reducing gallbladder polyp size by 2mm or more measure: Modification of the expected follow up sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06278077 id: C2104 id: 2022-003565-38 type: EUDRACT_NUMBER briefTitle: Neurexan - a Clinical Trial in Short-Term Insomnia Patients overallStatus: RECRUITING date: 2023-09-04 date: 2024-12-31 date: 2024-12-31 date: 2024-02-26 date: 2024-02-26 name: Biologische Heilmittel Heel GmbH class: INDUSTRY briefSummary: This clinical study aims to understand the effects of a medication called Neurexan on sleep patterns and stress in people with short-term insomnia. The study involves comparing Neurexan to a placebo - a tablet that looks like Neurexan but lacks active ingredients. The main goal of the study is to determine if Neurexan can enhance sleep efficiency in those with short-term insomnia. Sleep efficiency, which is the proportion of time spent asleep in relation to total time in bed, including attempts to fall asleep, will be assessed through Polysomnography (PSG). PSG examines various sleep characteristics such as brain activity, muscle and heart activity, and breathing.
The study will also investigate Neurexan's impact on stress levels. This will be assessed using the Cold Pressor Test, which measures stress through having the participant immerse their hand into ice water, and measuring changes in blood pressure and heart rate, both indicators of stress. In addition, blood and saliva samples collected before and after treatment with Neurexan or placebo, will be analyzed for stress-related hormones such as cortisol. Patient questionnaires and Electroencephalography (EEG), a non-invasive brain activity recording, will further assess stress symptoms.
Researchers will analyze data related to sleep efficiency, sleep quality, and stress symptoms. By comparing outcomes before and after Neurexan or placebo treatment, the study aims to detect improvements in these areas. Positive results with Neurexan but not with the placebo would provide robust evidence for Neurexan's efficacy in addressing sleep and stress management issues. This study contributes valuable insights into Neurexan's potential benefits for individuals with short-term insomnia. conditions: Insomnia conditions: Stress Reaction studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, double-blind, active- and placebo-controlled confirmatory clinical trial primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: All involved personnel at the investigational site, the Sponsor (except production unit) and the CRO (except independent biostatistician for performing the randomization) will be blinded during the trial. The Investigator keeps the sealed treatment code envelopes throughout the course of the trial for the individual patients and must not break the code without a valid reason (e.g., in case of emergency). whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Neurexan name: Placebo measure: Change from baseline in Sleep Efficiency. measure: Change from baseline in sleep pattern characterized by Number of Awakenings. measure: Change from baseline in daytime performance assessed by Epworth Sleepiness Scale patient questionnaire. measure: Ecological Momentary Assessments - continuous daily stress assessment. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jena University Hospital, Department of Psychiatry & Psychotherapy status: RECRUITING city: Jena state: Thuringia zip: 07743 country: Germany name: Martin Walter, MD role: CONTACT phone: +49 (0)3641 9390101 email: Martin.Walter@med.uni-jena.de lat: 50.92878 lon: 11.5899 hasResults: False
nctId: NCT06278064 id: BFHHZML20240006 briefTitle: Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers Diagnosis overallStatus: RECRUITING date: 2024-02-01 date: 2024-12-31 date: 2025-06-30 date: 2024-02-26 date: 2024-02-26 name: Beijing Friendship Hospital class: OTHER briefSummary: This study constitutes a case-control investigation employing a retrospective approach. Plasma samples from individuals with esophageal cancer, benign esophageal diseases, gastric cancer, benign gastric diseases, and a healthy control group were systematically collected. Advanced Data-Independent Acquisition (DIA) proteomics and single-vesicle membrane protein detection techniques were employed to quantify protein content within exosomes. Specific protein biomarkers indicative of early-stage upper gastrointestinal tumors were identified. External validation of these protein markers was conducted using Parallel Reaction Monitoring (PRM) technology on an independent validation cohort. The objective is to establish protein marker predictions for early diagnosis of upper gastrointestinal tumors and prognostication of therapeutic efficacy. conditions: Gastric Cancer conditions: Esophagus Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 562 type: ESTIMATED name: Gastric Cancer name: Esophagus Cancer measure: Plasma proteins in patients with gastric cancer measure: Plasma proteins in patients with esophagus cancer sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: The Fourth Hospital of Hebei Medical University status: RECRUITING city: Shijiazhuang state: Hebei country: China name: Lianmei Zhao, Ph.D. role: CONTACT lat: 38.04139 lon: 114.47861 facility: Beijing Friendship Hospital, Capital Medical University status: RECRUITING city: Beijing country: China name: Li Min, Ph.D. role: CONTACT name: Li Min, Ph.D role: PRINCIPAL_INVESTIGATOR name: Chenjie Xu, Ph.D role: SUB_INVESTIGATOR lat: 39.9075 lon: 116.39723 facility: Cancer Hospital Chinese Academy of Medical Sciences status: RECRUITING city: Beijing country: China name: Yibin Xie, Ph.D role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06278051 id: 21411 briefTitle: An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism overallStatus: RECRUITING date: 2024-02-19 date: 2024-12-31 date: 2024-12-31 date: 2024-02-26 date: 2024-04-18 name: Bayer class: INDUSTRY name: Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical Research & Development L.L.C.) briefSummary: This is an observational study in which only data will be collected from children with venous thromboembolism who are prescribed rivaroxaban or warfarin by their doctors.
* The occurrence of major bleeding and bleeding of importance in children who are taking drugs called anti platelet agents and NSAIDs to prevent blood clots at the same time as rivaroxaban, who are taking a drug that blocks the action of a protein called 'CYP3A4' at the same time as rivaroxaban, who have reduced kidney function, who have taken rivaroxaban for a long time, or who have taken other drugs by mouth to prevent blood clots before starting rivaroxaban
In this study, only available data from routine care are collected. No visits or tests are required as part of this study conditions: Venous Thromboembolism studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED name: Rivaroxaban granules for oral suspension name: Warfarin measure: Incidence of major bleeding in participants treated with rivaroxaban measure: Clinical characteristics and demographics of participants with pediatric VTE treated with rivaroxaban measure: Incidence of major bleeding in participants treated with warfarin measure: Incidence of bleeding important in pediatrics in participants treated with rivaroxaban and treated with warfarin as reference measure: Incidence of major bleeding and bleeding important in pediatrics in participants treated with rivaroxaban and in special target patient groups sex: ALL minimumAge: 0 Months maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Many facilities status: RECRUITING city: Multiple Locations country: Japan facility: Bayer status: RECRUITING city: Osaka zip: 530-0001 country: Japan lat: 34.69374 lon: 135.50218 hasResults: False
nctId: NCT06278038 id: NO.0057 in 2024 Ethical Review briefTitle: Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder overallStatus: NOT_YET_RECRUITING date: 2024-02-29 date: 2024-12-31 date: 2024-12-31 date: 2024-02-26 date: 2024-02-29 name: First Affiliated Hospital of Zhejiang University class: OTHER briefSummary: The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of major depression disorder compared to venlafaxine hydrochloride sustained-release tablets, to provide evidence-based basis for clinical rational drug use. conditions: Major Depression Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Toludesvenlafaxine hydrochloride sustained-release tablets name: Venlafaxine hydrochloride sustained-release tablets measure: Snaith-Hamilton Pleasure Scale (SHAPS) Total Score measure: Snaith-Hamilton Pleasure Scale (SHAPS) Total Score measure: Snaith-Hamilton Pleasure Scale (SHAPS) Reductive Rate measure: Dimensional Anhedonia Rating Scale (DARS) Score measure: Montgomery-Asberg Depression Rating Scale (MADRS) Score measure: 17-item Hamilton Depression Rating Scale (HAM-D17) Score measure: Sheehan Disability Scale (SDS) Score measure: Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Score measure: Treatment Emergent Symptom Scale (TESS) Score measure: Arizona Sexual Experience Scale (ASEX) Score measure: Count of red blood cell in blood measure: Count of white blood cell in blood measure: Count of platelet in blood measure: Concentration of hemoglobin in blood measure: Concentration of alanine aminotransferase in blood measure: Concentration of aspartate aminotransferase in blood measure: Concentration of gamma-glutamyltransferase in blood measure: Concentration of blood glucose in blood measure: Concentration of serum creatinine in blood measure: Concentration of urea in blood measure: Concentration of total cholesterol in blood measure: Concentration of high density lipoprotein in blood measure: Concentration of low density lipoprotein in blood measure: Concentration of triglyceride in blood measure: Concentration of protein in urine measure: Concentration of sugar in urine measure: Count of white blood cell in urine measure: Count of red blood cell in urine measure: ECG QT Interval measure: Changes in weight measure: Changes in pulse measure: Changes in both systolic and diastolic blood pressure measure: Changes in respiration rate measure: Changes in armpit temperature sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06278025 id: GO 19/833 briefTitle: Dysphagia and Deep Cervical Flexor Muscles overallStatus: COMPLETED date: 2019-09-01 date: 2024-02-01 date: 2024-02-01 date: 2024-02-26 date: 2024-03-18 name: Atılım University class: OTHER briefSummary: Cervical posture is vital for normal swallowing function. Changes in cervical posture during swallowing alter the bolus flow and swallowing kinematics through changes in gravity and oropharyngeal space. The hyoid bone does not articulate with any bone, so it requires adequate tension of the hyolaryngeal complex and proper cervical postural alignment to maintain its stabilization and position. Changes in cervical posture and stabilization can cause changes in hyoid bone position and kinematics through muscles and ligaments which may lead to decrease in hyoid elevation, loss of optimal strength of the suprahyoid and infrahyoid muscles due to disrupted length-tension relationship, and an increased risk of aspiration due to insufficient laryngeal elevation. Further, deterioration in cervical posture and decreased stabilization resulting from cervical muscle weakness or/both endurance could affect the control and strength of masticatory muscles, tongue muscles and suprahyoid - infrahyoid muscles, which are involved in swallowing function. Whereby DCF weakness gives rise to inadequate cervical stabilization, change in hyoid bone stabilization, alterations in suprahyoid and infrahyoid muscle function, and decreased laryngeal elevation may adversely affect the normal function of the swallowing related muscles. Thus, decreased cervical stabilization, which is often seen in neurological diseases, may be related to neurogenic dysphagia. Given the known changes in cervical stabilization as a consequence of neurologic injury, the additional impact on swallowing or a potentially already neurologically-disordered swallow is considered. Thus, loss of cervical stabilization may be one of the factors affecting dysphagia in patients with neurological diseases providing more information on all potential factors contributing to swallow impairment, potentially leading to more targeted and effective swallowing interventions. However, there is no study investigating the role of the DCF muscles in dysphagia. Therefore, the aim of the present study was to comparison of deep cervical flexor muscle strength and endurance in patients with and without neurogenic dysphagia. conditions: Dysphagia conditions: Neurological Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 30 type: ACTUAL name: assessment measure: dcf muscle strenght measure: dcf endurance sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Atilim University city: Ankara state: Incek zip: 06830 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06278012 id: E-59394181-604.01.02-32288 briefTitle: Development of Atılım Kinesiophobia Scale overallStatus: RECRUITING date: 2024-01-01 date: 2024-03-30 date: 2024-03-30 date: 2024-02-26 date: 2024-04-01 name: Atılım University class: OTHER briefSummary: Background:
In the first stage of the study, research on kinesiophobia was reviewed and a total of 38 questions were created for the scale. The questions were submitted to the opinion of 11 experts working in the physiotherapy and rehabilitation field. Then A total of 100 patients with acute and chronic musculoskeletal pain completed the Turkish Atılım Kinesiophobia Scale and Tampa Scale of Kinesiophobia. conditions: Kinesiophobia conditions: Acute Pain conditions: Chronic Pain conditions: Fear of Movement studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 150 type: ESTIMATED measure: The pilot study of the scale will be conducted with a total of 40 patients, 10 participants for each patient group. measure: item analyses and exploratory factor analysis (EFA) analysis will be performed with a sample size of 5 times the number of questions in the item pool with acute and chronic pain patients. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Atılım University status: RECRUITING city: Ankara country: Turkey name: Naime Uluğ, PhD. role: CONTACT phone: +905365434409 email: naime.ulug@atilim.edu.tr lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06277999 id: D8820C00001 briefTitle: C.Difficile Observational Study overallStatus: NOT_YET_RECRUITING date: 2024-02-28 date: 2024-10-11 date: 2024-10-11 date: 2024-02-26 date: 2024-02-26 name: AstraZeneca class: INDUSTRY briefSummary: D8820C00001 is an exploratory, non-interventional, unblinded, observational study evaluating the acceptability, feasibility and performance of methods to collect, transport and test biospecimens in participants ≥ 18 years of age with an active CDI. Participants will also be monitored for recurring episodes of diarrhea and will need to complete validated PROs and study evaluation questionnaires conditions: Clostridium Infections studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED measure: Number of participants that completed key study activities according to protocol measure: Time intervals across stool sample collection logistics measure: Participant Experience and site staff evaluation questionnaires measure: Gather information to assess logistics, resourcing and performance of different toxin detection assays (eg. EIA, PCR, CCNA) sex: ALL minimumAge: 18 Years maximumAge: 130 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06277986 id: KY20212018-F-2 briefTitle: Early Diagnosis of Gastric Cancer Cachexia overallStatus: RECRUITING date: 2021-06-01 date: 2024-09-01 date: 2024-09-01 date: 2024-02-26 date: 2024-02-26 name: Xijing Hospital class: OTHER briefSummary: Gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest. In cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia. However, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment. Therefore, it is important to find biomarkers for early detection of cachexia. The investigators carried out a plasma-derived exosomal microRNA(miRNA) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia. conditions: Cachexia studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 150 type: ESTIMATED name: cachexia measure: BMI sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fourth Military Medical University status: RECRUITING city: Xi'an state: Shaanxi country: China name: Jipeng Li role: CONTACT phone: +86-029-84771533 lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06277973 id: 0007551-2 briefTitle: Feasibility Study of the Self-Care Immediate Stabilization Procedure (ISP) ® After a Traumatic Experience overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-01 date: 2025-05 date: 2024-02-26 date: 2024-03-27 name: Tel Aviv University class: OTHER briefSummary: The study aims to assess the feasibility of an online intervention platform based on the Immediate Stabilization Procedure (ISP®). This intervention targets early trauma reactions, aiming to reduce the risk of future PTSD. conditions: Post-traumatic Stress Disorder conditions: Acute Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomly allocated to one of the following groups: the experiment group and the waiting list group. Each group will receive the intervention but in the waiting list group this will occur a week later:
Day 1 - questionnaires (T0) Day 7 - questionnaires (T1) Day 11- intervention Day 14- questionnaires (T2) Day 104- follow up questionnaires (T3) The parallel element of this model lies in the first week of the study: the experiment group goes through 2 measurements with the intervention in the middle of the week, whereas the waiting list group goes through 2 measurements without the intervention. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Participants will be informed that the intervention will occur between 2 days and 14 days and that they will fill 3-4 surveys. They will not be aware that there are two groups. whoMasked: PARTICIPANT count: 200 type: ESTIMATED name: Eye Movement Desensitization and Reprocessing (EMDR) measure: PCL-5 (Posttraumatic Stress Disorder Checklist) measure: GAD-7 (General Anxiety Disorder-7) measure: SSASI (The Short Scale Anxiety Sensitivity Index) measure: BSI 18 (Brief Symptom Inventory) measure: DES-II (Dissociative Experiences Scale) measure: DERS (Difficulties in Emotion Regulation Scale) measure: NSESSS (The National Stressful Events Survey Acute Stress Disorder Short Scale) measure: SASRQ (Stanford Acute Stress Reaction Questionnaire) measure: Exposure to traumatic event during the current war measure: PDEQ (Peritraumatic Dissociative Experiences Questionnaire) measure: TIS (Tonic Immobility Scale) measure: PDI (The Peritraumatic Distress Inventory) measure: Questionnaires to test user experience of the system measure: Questionnaire for examining the experience of the intervention measure: Qualitative interview measure: Questionnaire regarding receiving emotional treatment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tel Aviv University city: Tel Aviv country: Israel lat: 32.08088 lon: 34.78057 hasResults: False
nctId: NCT06277960 id: CNS2301 briefTitle: Septal Ablation for Obstructive HCM overallStatus: NOT_YET_RECRUITING date: 2024-02-29 date: 2024-06-30 date: 2024-11-30 date: 2024-02-26 date: 2024-02-26 name: SuZhou Sinus Medical Technologies Co.,Ltd class: INDUSTRY briefSummary: Hypertrophic cardiomyopathy (HCM) is a common clinical genetic-related disease, with a global incidence of 0.2%-0.5%, but only a few cases (10-20%) have been clinically diagnosed. About 70% of them are hypertrophic obstructive cardiomyopathy (HOCM), these HOCM patients have significant clinical symptoms, including progressively increasing fatigue, angina, exertional dyspnea, and syncope. Conservative medications are used to treat the vast majority of patients. Invasive therapy, which includes surgical myectomy, percutaneous transluminal septal myocardial ablation(PTSMA), percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) and percutaneous endocardial septal radiofrequency ablation (PESA) is introduced to patients with refractory symptoms or drug resistance. However, surgical operations are complicated and high risk procedures with high mortality. Interventional approaches are very difficult to perform and therefore the application is limited.
Previous researches have shown that interventricular septal radiofrequency ablation could effectively reduce the left ventricular outflow tract pressure gradient (LVOTG), thereby treating obstructive hypertrophic cardiomyopathy (HOCM). This device is based on the same radiofrequency ablation energy principle, however, the catheter is introduced into the right ventricle and performs ablation treatment on the hypertrophic interventricular septum, which is potentially a lower risk route of access for septal ablation than currently attempted interventional approaches.
The purpose of this study is to evaluate the safety and efficacy of percutaneous intramyocardial septal ablation catheters in the treatment of obstructive hypertrophic cardiomyopathy. conditions: Hypertrophic Obstructive Cardiomyopathy (HOCM) studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: percutaneous intramyocardial septal radiofrequency ablation system measure: 30-day major adverse clinical events (MACE) measure: Technical success rate measure: Short Form 36 (SF-36) health survey questionnaire measure: Improvement of left ventricular outflow tract gradient (LVOTG) measure: Improvement of NYHA functional classification measure: 6-min walk distance sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sir Run Run Shaw Hospital city: Hangzhou state: Zhejiang zip: 310016 country: China name: Yaxun Sun, MD role: CONTACT phone: +86 15057173170 email: sunyaxun@zju.edu.cn lat: 30.29365 lon: 120.16142 hasResults: False